HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Phase 2
Active, not recruiting
NCT04619004
| Condition | Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Daiichi Sankyo |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 277 participants |
|---|
| Interventions | Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration) |
|---|
| Start date | Feb 2, 2021 |
|---|
| Completion date | Nov 21, 2022 |
|---|
| Results posted | Apr 2, 2024 |
|---|
Summary
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months · Participants
| Patritumab Deruxtecan 5.6 mg/kg | 64 Participants |
|---|
| Patritumab Deruxtecan Up-Titration | 8 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.